|
ALG2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.00829999905017E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.56180000043804E-07 |
| Normal-vs-Stage2 |
1.117390E-03 |
| Normal-vs-Stage3 |
4.85069762135026E-11 |
| Normal-vs-Stage4 |
4.05175892836951E-12 |
| Stage1-vs-Stage2 |
6.602000E-01 |
| Stage1-vs-Stage3 |
2.839900E-03 |
| Stage1-vs-Stage4 |
3.55590000000738E-05 |
| Stage2-vs-Stage3 |
2.149900E-02 |
| Stage2-vs-Stage4 |
8.592500E-04 |
| Stage3-vs-Stage4 |
7.160000E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.45909959062374E-11 |
| Normal-vs-AfricanAmerican |
4.06149999999661E-05 |
| Normal-vs-Asian |
1.628570E-04 |
| Caucasian-vs-AfricanAmerican |
5.294800E-01 |
| Caucasian-vs-Asian |
6.806300E-02 |
| AfricanAmerican-vs-Asian |
1.306210E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.33730027052081E-10 |
| Normal-vs-Female |
2.75999999521659E-08 |
| Male-vs-Female |
3.725600E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.78569999956346E-07 |
| Normal-vs-Age(41-60Yrs) |
2.09390005334598E-09 |
| Normal-vs-Age(61-80Yrs) |
5.07529995807943E-09 |
| Normal-vs-Age(81-100Yrs) |
6.179600E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.264000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.126000E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.867400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.620570E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.480600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.504000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.224810E-04 |
| Classical-VS-Follicular |
3.890600E-01 |
| Classical-VS-Other |
2.281400E-01 |
| Classical-VS-Normal |
8.85899997804529E-09 |
| Tall-VS-Follicular |
1.643520E-04 |
| Tall-VS-Other |
6.250800E-01 |
| Tall-VS-Normal |
1.28459465287278E-11 |
| Follicular-VS-Other |
2.077400E-01 |
| Follicular-VS-Normal |
2.371100E-04 |
| Other-VS-Normal |
1.158270E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.5651599999944E-05 |
| Normal-vs-N1 |
2.73889999569121E-09 |
| N0-vs-N1 |
1.024310E-02 |
|
|
